david-meek

Novartis’ David Meek moves to Endocyte

pharmafile | July 30, 2012 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing David Meek, Endocyte, Novartis, appointment 

David Meek has been appointed to the newly created position of chief commercial officer at the biotechnology firm Endocyte.

Meek will be responsible for the development of Endocyte’s commercial team and the company’s overall commercial strategy and execution.

“David’s extensive, senior, global commercial experience and track record of launch success make him an ideal choice to build our sales and marketing capabilities as we prepare to commercialise our lead cancer drug candidate, vintafolide, and our companion imaging diagnostic, etarfolatide,” said Ron Ellis, Endocyte’s president and chief executive.

“David’s appointment adds breadth to our already strong management team and represents an important step in the next phase of our development.”

Meek brings more than 20 years of pharma experience to the firm, including general management in North America and Europe, and numerous successful launches for oncology and specialty products.

He comes to Endocyte after more than seven years at Novartis, where he was most recently the head of northern and central Europe oncology and launched key new oncology products and indications for Novartis.

Previously, he served as president and chief executive of Novartis Pharmaceuticals Canada, where he oversaw the launch of Lucentis and other specialty products, and he also served as the global business franchise head for Novartis’ respiratory and dermatology franchise in Basel, Switzerland.

Prior to joining Novartis, Meek was at Johnson & Johnson for 15 years, where he held a variety of senior sales and marketing roles across multiple therapeutic areas, including oncology.

Related Content

PeptiDream and Novartis extend peptide discovery collaboration

PeptiDream has announced the expansion of its peptide discovery collaboration with Novartis Pharma AG.

Novartis shares new data about Fabhalta for IgAN treatment

Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …

chuttersnap-oijvdm3zx4i-unsplash

Novartis shares new data for Zolgensma in children with SMA

Novartis has announced new data to continue the support of the clinical benefits of Zolgensma …

Latest content